A Phase 3 clinical trial update for zilebesiran was recorded on September 18, 2026. The trial, registered as NCT07181109, is titled "Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease." The study status is listed as recruiting. This trial is being conducted in Phase 3 and targets patients whose hypertension is not adequately controlled. Eligible participants include those with either established cardiovascular disease or a high risk for cardiovascular disease. No results have been posted for this trial at this time. The event data does not include information on efficacy, safety outcomes, or trial completion. This is an update on trial status and design only. Readers seeking more background on zilebesiran, including its regulatory status and general information, can consult the compound overview for further context.
Phase 3 Zilebesiran Trial in Hypertension Now Recruiting
See the full angiotensin ii overview
Source: https://clinicaltrials.gov/study/NCT07181109